{"id":"W4412592901","doi":"10.1177/13524585251355842","title":"Brain atrophy and associations with long-term disability and cognitive function in participants with relapsing multiple sclerosis treated with ozanimod: Results from phase 3 and open-label extension trials","year":2025,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Janssen Pharmaceuticals; EMD Serono; MedDay Pharmaceuticals; Innosuisse - Schweizerische Agentur für Innovationsförderung; Kiniksa Pharmaceuticals; Shionogi; Genentech; National Multiple Sclerosis Society; Horizon Therapeutics; Celltrion; Atara Biotherapeutics; National Institutes of Health; Mylan; TG Therapeutics; European Committee for Treatment and Research in Multiple Sclerosis; Sanofi; Multiple Sclerosis International Federation; University of Pennsylvania; Alexion Pharmaceuticals; Neuraxpharm; Teva Pharmaceutical Industries; Bayer HealthCare; European Commission; Celgene; Biogen; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Atrophy; Multiple sclerosis; Physical therapy; Internal medicine; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003733653,0.0005540053,0.0009542201,0.0002391527,0.0002436256,0.0005468227,0.0004741412,0.0006836392,0.001449919],"category_scores_gemma":[0.002320281,0.0001978487,0.001175863,0.0003626826,0.0004438605,0.0004479446,0.0003577104,0.0006786945,0.0001372184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003080572,"about_ca_system_score_gemma":0.0005211212,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007004954,"about_ca_topic_score_gemma":0.002080087,"domain_scores_codex":[0.999007,0.000590091,0.0001034151,0.0001003772,0.0001339278,0.00006514041],"domain_scores_gemma":[0.9974667,0.0005359357,0.001322967,0.0001230741,0.0002902047,0.0002610444],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7042664,0.006464853,0.1517394,0.003616095,0.009156428,0.0001173347,0.0005981041,0.0005284113,0.0176213,0.00009786557,0.001147062,0.1046469],"study_design_scores_gemma":[0.1431965,0.1633577,0.6757981,0.0004371589,0.008007995,0.0004190548,0.0003832454,0.0006945978,0.004115137,0.0002263196,0.003287028,0.00007705786],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952505,0.00343609,0.0001342921,0.0001032115,0.00001921085,0.0002728319,0.0004635772,0.000009853476,0.0003104492],"genre_scores_gemma":[0.9966428,0.001363556,0.0006179735,0.0001098904,0.00004050912,0.0003862143,0.0006182755,0.000004778532,0.0002160446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003733653,"threshold_uncertainty_score":0.01974565,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2598316333941632,"score_gpt":0.3896488495859778,"score_spread":0.1298172161918146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}